ReviewInternational urology and nephrology2025
Advances in organ protection: ischemic preconditioning and erythropoietin as protective strategies.
Review in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIschemic preconditioning (IPC) and erythropoietin (EPO) are known for their protective effects against organ damage caused by ischemia, ischemia-reperfusion (I/R), and certain drugs. This review aims to summarize the literature on IPC and EPO, focusing on their mechanisms and exploring their relationship in organ protection.
methodsA comprehensive search of PubMed databases was conducted using keywords, such as IPC, EPO, ischemia-reperfusion, and organ protection. Articles were screened for relevance to IPC or EPO-mediated organ protection, excluding studies on hypoxic preconditioning and pharmacological preconditioning.
resultsIPC and EPO have demonstrated protective effects across various organs, including kidneys, liver, heart, small intestine, retina, stomach, pancreas, and nervous system. They exert their effects through anti-apoptotic, anti-oxidative stress, and anti-inflammatory mechanisms involving distinct signaling pathways. Evidence suggests a potential interaction between IPC and EPO, with IPC potentially elevating serum EPO levels and EPO enhancing the protective effects of IPC, particularly in the heart via the JAK-STAT pathway.
conclusionsIPC and EPO hold promise as therapeutic strategies for mitigating organ damage in ischemic conditions. Further research is needed to elucidate their interaction in organ protection given the current limitations in evidence. Nonetheless, their individual mechanisms and clinical applications underscore their potential utility in clinical settings.
Indexed as
Identifiers
40455321What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.